Key result
In patients with newly diagnosed heart failure, physical activity measured by a wearable cardioverter defibrillator significantly increased by a mean of 1,167 daily steps from the first two weeks to the last two weeks of surveillance.
Why the study?
Wearable cardioverter defibrillator telemonitoring features enable physical activity evaluation, leading researchers to assess physical activity in patients with newly diagnosed heart failure.
Observational (n=77)
No
Mean Difference: 1167.1
Absolute Event Rate: 6119.6% vs 4952.6%
p-value: p=<0.001
Wearable cardioverter defibrillators can effectively monitor physical activity in newly diagnosed heart failure patients, demonstrating significant improvements in daily steps that do not necessarily correlate with LVEF recovery.
WCD-derived physical activity data in new HF may aid monitoring; leaves open prognostic or therapeutic utility pending prospective validation.
Background The wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure. Methods We collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included. Results Seventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p -value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA. Conclusion The WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment.
No takes yet. Share an insight, caveat, or question.
Iliodromitis et al. (2023) conducted an observational in Newly diagnosed heart failure with severely reduced ejection fraction (n=77). Wearable cardioverter defibrillator (WCD) vs. First two weeks of surveillance was evaluated on Physical activity measured by daily steps (MD 1167.1, p=<0.001). In patients with newly diagnosed heart failure, physical activity measured by a wearable cardioverter defibrillator significantly increased by a mean of 1,167 daily steps from the first two weeks to the last two weeks of surveillance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: